These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH; Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257 [TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Contemporary P2Y Yun JE; Kim YJ; Park JJ; Kim S; Park K; Cho MS; Nam GB; Park DW J Am Heart Assoc; 2019 Jul; 8(14):e012078. PubMed ID: 31310570 [TBL] [Abstract][Full Text] [Related]
9. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684 [TBL] [Abstract][Full Text] [Related]
10. Prasugrel in the treatment of acute coronary syndrome. Spartalis M; Tzatzaki E; Spartalis E; Paschou SA; Athanasiou A; Iliopoulos DC; Siasos G; Voudris V Future Cardiol; 2020 Nov; 16(6):559-568. PubMed ID: 32390477 [TBL] [Abstract][Full Text] [Related]
12. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis. Wang Z; Zhou DY; Su Y; Si LY; Xu Q BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560 [TBL] [Abstract][Full Text] [Related]
13. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y O'Donoghue ML; Murphy SA; Sabatine MS Circulation; 2020 Aug; 142(6):538-545. PubMed ID: 32551860 [TBL] [Abstract][Full Text] [Related]
14. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis. De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567 [TBL] [Abstract][Full Text] [Related]
15. Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis. Rodriguez AE; Rodriguez-Granillo AM; Ascarrunz SD; Peralta-Bazan F; Cho MY Curr Pharm Des; 2018; 24(4):465-477. PubMed ID: 29308737 [TBL] [Abstract][Full Text] [Related]
16. Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis. Komosa A; Lesiak M; Krasiński Z; Grygier M; Siniawski A; Skorupski W; Olasińska-Wiśniewska A; Pyda M; Araszkiewicz A; Mitkowski P; Grajek S; Mularek-Kubzdela T; Hengstenberg C; Siller-Matula JM Thromb Haemost; 2019 Jun; 119(6):1000-1020. PubMed ID: 30919382 [TBL] [Abstract][Full Text] [Related]
17. P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes. Sachdeva A; Mutyala R; Mantri N; Zhu S; McNulty E; Solomon M J Interv Cardiol; 2023; 2023():1147352. PubMed ID: 37251366 [TBL] [Abstract][Full Text] [Related]
18. Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome. Shah R; Rashid A; Hwang I; Fan TM; Khouzam RN; Reed GL Am J Cardiol; 2017 Jun; 119(11):1723-1728. PubMed ID: 28385176 [TBL] [Abstract][Full Text] [Related]